Advertisement

Neurochemical Journal

, Volume 8, Issue 2, pp 115–120 | Cite as

The relationship between the anxiolytic action of selank and the level of serotonin in brain structures during the modeling of alcohol abstinence in rats

  • A. V. Nadorova
  • L. G. Kolik
  • P. M. Klodt
  • V. B. Narkevich
  • P. L. Naplyokova
  • M. M. Kozlovskaya
  • V. S. Kudrin
Experimental Articles

Abstract

We studied the in vivo effects of the peptide anxiolytic selank (0.3 mg/kg) on the behavioral parameters of the syndrome of alcohol withdrawal and the neurochemical indices of the serotonergic system in the brain structures in ex vivo experiments in outbred rats with a preference for a 10% solution of ethanol. We found that a single administration of selank eliminates the anxious response in the elevated plus maze at 48 h after the withdrawal of ethanol and increases the time spent in the open arms and the number of entries into the open arms. Using HPLC, we showed that selank prevents an increase in the serotonin level in the frontal cortex, hypothalamus, and amygdala, which may be related to a decrease in the synthesis of serotonin. The data we obtained indicate that selank has anxiolytic activity under conditions of alcohol abstinence, which suggests that the sphere of its use in clinical practice may be widened.

Keywords

selank syndrome of ethanol withdrawal serotonin anxiety rats 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Koob, G.F. and Le Moal, M., Science, 1997, vol. 278, pp. 52–58.PubMedCrossRefGoogle Scholar
  2. 2.
    File, S.E., Andrews, N., Al-Farhan, M., and Wu, P.Y., Alcohol Alcohol., Suppl., 1993, vol. 2, pp. 495–499.Google Scholar
  3. 3.
    June, H.L., Torres, L., Cason, C.R., Hwang, B.H., Braun, M.R., and Murphy, J.M., Brain Res., 1998, vol. 784, pp. 256–275.PubMedCrossRefGoogle Scholar
  4. 4.
    Gatch, M.B., Wallis, C.J., and Lal, H., Alcohol, 1999, vol. 19, pp. 207–211.PubMedCrossRefGoogle Scholar
  5. 5.
    Rubio, M., Fernandez-Ruiz, J., de Miguel, R., Maestro, B., Michael Walker, J., and Ramos, J.A., Neuropharmacol., 2008, vol. 54, no. 6, pp. 976–988.CrossRefGoogle Scholar
  6. 6.
    Maccioni, P., Colombo, G., and Carai, M.A., CNS Neurol. Disord. Drug Targets, 2010, vol. 9, no. 1, pp. 55–59.PubMedCrossRefGoogle Scholar
  7. 7.
    Overstreet, D.H., Knapp, D.J., Angel, R.A., Navarro, M., and Breese, G.R., Psychopharmacology (Berl.), 2006, vol. 187, pp. 1–12.CrossRefGoogle Scholar
  8. 8.
    Knapp, D.J., Overstreet, D.H., Moy, S.S., and Breese, G.R., Alcohol, 2004, vol. 32, no. 2, pp. 101–111.PubMedCentralPubMedCrossRefGoogle Scholar
  9. 9.
    Neznamov, G.G., Teleshova, E.S., and Bochkarev, V.K., Psikhiatriya, 2003, no. 4, pp. 2–36.Google Scholar
  10. 10.
    Seredenin, S.B., Kozlovskaya, M.M., and Semenova, T.P., Klin. Farmakol. Toksikol., 1995, vol. 58, no. 6, pp. 3–6.Google Scholar
  11. 11.
    Narkevich, V.B., Kudrin, V.S., Klodt, P.M., Pokrovskii, A.A., Kozlovskaya, M.M., Maiskii, A.I., and Raevskii, K.S., Eksper. Klin. Farmakol., 2008, vol. 71, no. 5, pp. 28–31.Google Scholar
  12. 12.
    Semenova, T.P., Kozlovskii, I.I., Zakharova, N.M., and Kozlovskaya, M.M., Eksper. Klin. Farmakol., 2009, vol. 72, no. 4, pp. 6–8.Google Scholar
  13. 13.
    Timberlake, W., Leffel, J.K., Chester, J.A., and Froehlich, J.C., Alcohol, 2009, vol. 43, no. 2, pp. 105–118.PubMedCentralPubMedCrossRefGoogle Scholar
  14. 14.
    Rodd, Z.A., Bell, R.L., Kuc, K.A., Murphy, J.M., Lumeng, L., Li, T.K., and Mcbride, W.J., Neuropsychopharmacol., 2003, vol. 28, no. 9, pp. 1614–1621.CrossRefGoogle Scholar
  15. 15.
    Rodd-Henricks, Z.A., McKinzie, D.L., Murphy, J.M., Mcbride, W.J., Lumeng, L., and Li, T.K., Alcohol Clin. Exp. Res, 2000, vol. 24, no. 6, pp. 747–753.PubMedGoogle Scholar
  16. 16.
    Pellow, S., Chopin, P., File, S.E., and Briley, M., J. Neurosci. Methods, 1985, vol. 14, pp. 149–67.PubMedCrossRefGoogle Scholar
  17. 17.
    Breese, G.R., Overstreet, D.H., and Knapp, D.J., Psychopharmacology (Berl.), 2005, vol. 178, no. 4, pp. 367–380.CrossRefGoogle Scholar
  18. 18.
    Kash, T.L., Alcohol, 2012, vol. 46, no. 4, pp. 303–308.PubMedCentralPubMedCrossRefGoogle Scholar
  19. 19.
    Pandey, S.C., Piano, M.R., Schwertz, D.W., Davis, J.M., and Pandey, G.N., Alcohol Clin. Exp. Res., 1992, vol. 16, pp. 1110–1116.PubMedCrossRefGoogle Scholar
  20. 20.
    Heisler, L.K., Zhou, L., Bajwa, P., Hsu, J., and Tecott, L.H., Genes. Brain Behav., 2007, vol. 6, pp. 491–496.PubMedCrossRefGoogle Scholar
  21. 21.
    Klodt, P.M., Kudrin, V.S., Narkevich, V.B., Kozlovskaya, M.M., Maiskii, A.I., and Raevskii, K.S., Psikhofarmakol. Biol. Narkol., 2005, vol. 5, no. 3, pp. 984–988.Google Scholar
  22. 22.
    Sarkisova, K.Yu., Kozlovskii, I.I., and Kozlovskaya, M.M., Zh. Vyssh. Nervn. Deyat. im. I.P. Pavlova, 2008, vol. 58, no. 2, pp. 226–237.Google Scholar
  23. 23.
    Narkevich, V.B., Klodt, P.M., Kudrin, V.S., Maiskii, A.I., and Raevskii, K.S., Psikhofarmakol. Biol. Narkol., 2007, vol. 7, no. 2, pp. 1563–1567.Google Scholar
  24. 24.
    Brousse, G., Arnaud, B., and Vorspan, F., Alcohol Alcohol., 2012, vol. 47, no. 5, pp. 501–508.PubMedCrossRefGoogle Scholar

Copyright information

© Pleiades Publishing, Ltd. 2014

Authors and Affiliations

  • A. V. Nadorova
    • 1
    • 2
  • L. G. Kolik
    • 1
  • P. M. Klodt
    • 1
  • V. B. Narkevich
    • 1
  • P. L. Naplyokova
    • 1
  • M. M. Kozlovskaya
    • 1
  • V. S. Kudrin
    • 1
  1. 1.Zakusov Institute of PharmacologyRussian Academy of Medical SciencesMoscowRussia
  2. 2.MoscowRussia

Personalised recommendations